Lenalidomide in combination with R-CHOP (R2-CHOP) as first-line treatment of patients with high tumour burden follicular lymphoma: a single-arm, open-label, phase 2 study - Role of intra-Clonal HEterogeneity and Leukemic environment in ThErapy Resistance of chronic leukemias Accéder directement au contenu
Article Dans Une Revue The Lancet Haematology Année : 2018

Lenalidomide in combination with R-CHOP (R2-CHOP) as first-line treatment of patients with high tumour burden follicular lymphoma: a single-arm, open-label, phase 2 study

Fichier non déposé

Dates et versions

hal-02329073 , version 1 (23-10-2019)

Identifiants

Citer

Hervé Tilly, Franck Morschhauser, Olivier Casasnovas, Thierry Jo Molina, Pierre Feugier, et al.. Lenalidomide in combination with R-CHOP (R2-CHOP) as first-line treatment of patients with high tumour burden follicular lymphoma: a single-arm, open-label, phase 2 study. The Lancet Haematology, 2018, 5 (9), pp.e403-e410. ⟨10.1016/S2352-3026(18)30131-5⟩. ⟨hal-02329073⟩
55 Consultations
0 Téléchargements

Altmetric

Partager

Gmail Facebook X LinkedIn More